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Ethnopharmacology†
David M. Taylora,b and Ursula Wernekec
aPharmacy Department Denmark Hill, Maudsley Hospital, London, UK; bKing’s College London Institute of Pharmaceutical Science, London,
UK; cDepartment of Clinical Sciences, Division of Psychiatry, Sunderby Research Unit, Umeå University, Umeå, Sweden
ABSTRACT
Background: Ethnopharmacology relates to the study of substances used medicinally by different eth-
nic or cultural groups or handling of, drugs-based ethnicity or pharmacogenetics.
Aims: To review the key aspects of ethnopharmacology.
Method: This lecture gives an overview of the relationship between geography, culture, pharmacogen-
omics and prescribing.
Results: Although the majority of antipsychotics, antidepressants and mood-stabilisers are widely and
cheaply available in generic forms, prescription rates can vary. Clozapine is one such example with
prescribing-rates ranging from less than 10 patients per 100,000 people to nearly 180 patients/100,000
people. Pharmacogenetic studies of antipsychotics and antidepressants concern gene polymorphisms
that may affect both, pharmacodynamic or pharmacokinetic properties. Considerable genetic and eth-
nic variability has been seen for the P450 microsomal enzymes CYP 2D6 and 1A2.
Conclusions: With accelerated global mobility and increased understanding of medicinal substances
at molecular level, understanding of ethnopharmacology will become increasingly important in routine
clinical practice.
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Introduction
The subject of ethnopharmacology encompasses two distinct
areas of study: substances used medicinally by different eth-
nic or cultural groups (e.g. folk remedies); and differences in
response to, or handing of, drugs-based ethnicity or pharma-
cogenetics. Both aspects share the same promise of step-
change advances in pharmacotherapy but neither has yet
delivered on this expectation.
Ethnopharmacology – geography, culture and
prescribing
The treatment of psychiatric disorders is perhaps somewhat
uniform around the world. The majority of antipsychotics,
antidepressants and mood-stabilisers have long since lost
any patent protection and are widely and cheaply available
in generic forms. Uniform availability does not, however,
always assure the uniform prescription rates. A good
example here is the use of clozapine. Christian Bachmann
and colleagues collected data on clozapine prescribing in 17
countries [1]. The rate of prescribing ranged from less than
10 patients per 100,000 people to nearly 180/100,000 people.
More striking than this variation was the varied pattern of
clozapine prescribing in each country. Lithuania, the highest
user of clozapine, showed perhaps the expected pattern:
minimal use in those aged under 19 and over 80 years and
peak used in those in middle age. Prescribing in Japan was
the lowest rate reported and was concentrated in patients
aged 20–49 years. In marked contrast, prescribing in
Columbia was concentrated almost entirely in those older
than 80 years of age. The United States and Sweden showed
usage in a similar pattern of Lithuania but with something of
a right-shift because of higher rates of prescribing in the
50þ group.
The reasons for the wide differences in overall use and in
patterns of use are far from clear. One obvious influence is
the time of introduction of clozapine. For example, clozapine
has been available in Japan for only a few years, so one
would perhaps not expect widespread prescribing. Another
factor is the difference in regulations relating to clozapine
prescribing. A study conducted in 2016 [2], found significant
variation in regulations for clozapine use across nine coun-
tries. Differences were found in licensed indications, fre-
quency of blood monitoring, thresholds for stopping
clozapine, definition of treatment resistance and even
licensed dose range. Tacit recognition of the power of regu-
lations to restrain clozapine use is provided by the introduc-
tion of the REMS (Risk Evaluation and Mitigation Strategy) in
the USA – one of the lowest uses of clozapine in the
Bachmann study. This scheme replaced all the individual
patient registries in an attempt to assure safe use and pro-
mote wider use of clozapine [3].
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Apart from clozapine use, perhaps the best example of
cultural variation in psychotropic use is of the St John’s
Word [4,5] – a natural product of variable content used
extensively in Germany and northern Europe but much less
so elsewhere.
Ethnopharmacology – pharmacogenetics
The concept of prescribing according to pharmacogenetics
characteristics offers the prospect of improved efficacy and
tolerability as a result of targeted interventions. Efforts have
been made to identify the genetic factors associated with
treatment response. This would allow specific drugs to be
used in specific patients with a high likelihood of response.
Where variation in response was found to be linked to recep-
tor genotype, this would provide insight into the mode of
action of the drug.
A review of studies examining clozapine response [6]
identified numerous gene polymorphisms associated with
good outcome. These included gene polymorphisms to D1,
D2, D3 and D4 receptors as well as those for 5HT2A, 5HT2C,
5HT6 receptors and numerous glutamine transporter genes.
The high number of statistically significant associations may
owe as much to the repeated application of statistical testes
as to true associations. The same is true for clozapine and
agranulocytosis where at least six gene polymorphisms were
identified as being linked to this adverse effect. And likewise,
olanzapine response where gene polymorphism associations
were reported for six genes (COMT, D3 (2 polymorphisms),
GRM3, 5HTT and MDR1).
The associations discovered so far have not as yet led to
any change in the way clozapine or olanzapine are pre-
scribed. The most startle differences in outcome according to
genotype have been identified for the antipsychotic iloperi-
done. In a controlled study versus ziprasidone [7], patients
were grouped according to the response to iloperidone and
combinations of six marker genes. The group with the most
favourable combination showed a response rate of 75%,
those with the least favourable just over 10%. The same
group [8] identified different genetic markets linked to
iloperidone’s effect on the QT interval. Other studies have
found 13 polymorphisms of a gene linked to antipsychotic-
associated weight gain [9].
In the most recent study [10], 2413 patients were ran-
domly assigned an individual antipsychotic treatment and
genome-wide associations were investigated. Five new gene
loci were found to be linked to response, most of these
being related to synaptic function. Nonetheless, the authors
of this study declared that their results had ‘scant clinical
utility’ at least at present.
Attempts to discover genetic predictors of response to
antidepressants have also been somewhat unproductive.
Combined results from three studies (GENDEP, MARS and
STARD) were unable to show any predictive associations
despite testing 1.2 million polymorphisms [11]. A further
attempt to pull out something from these expensive and
publically funded trials [12] found little of note. Other work-
ers suggest that 5HT2A receptor polymorphisms predict
response to antidepressants [13].
A somewhat better developed aspect of pharmacogenet-
ics is the study of the role of genetic variation in cytochrome
function and its relationship to drug dosing and response
[1–3]. Cytochromes and other phase I enzymes (alcohol
dehydrogenase, aldehyde dehydrogenase, etc.) are usually
found in the liver but also function in the gut wall and in
the brain. The speed with which cytochrome enzymes cata-
lyse reactions (and therefore rate of metabolism) is genetic-
ally determined. In poor metabolisers, drug metabolism is
slowed down. Thus, poor metabolizers are more prone to
adverse effects. Slower conversion to active metabolites can
potentially also lower efficacy. In rapid metabolisers, drug
metabolism is accelerated. Thus, drug elimination rates are
increases, and rapid metabolizers may need higher doses to
achieve efficacy. The table below shows the relative fre-
quency of poor and ultra-rapid metabolisers by CYP2D6 in
different ethnic groups [14] (Table 1). As most SSRIs and
many antipsychotics, including risperidone and aripiprazole
are substrates of CYP 2D6, a higher proportion of patients
from African or Middle Eastern background may experience
lower drug efficacy and require dose increases.
Another example is CYP 1A2, implicated for instance in
the metabolism of clozapine and olanzapine. Asian and
African populations may experience lower CYP 1A2 activity
than Caucasians [14,15]. For instance, one study showed that
Swedes had 1.5 times higher CYP 1A2 activity than Koreans
[15,16]. Thus, a higher proportion of patients from Asian and
African background may have an increased risk of adverse
effects and require dose decreases. The rate of CYP 1A2
reduction may also be influenced by other inducers, such as
tobacco smoke. However, 35–85% of the CYP 1A2 response
variability may be due to genetic factors [15,17].
Conclusions
With accelerated global mobility and increased understand-
ing of medicinal substances at molecular level, understand-
ing of ethnopharmacology will become increasingly
important in routine clinical practice. Ethnic variability of
pharmacogenetics factors should be considered as a poten-
tial cause for unexpected lack of effectiveness or increased
experience of adverse effects. Testing for genotype or
phenotype would inform drug choice and drug dose both
for CYP2D6 and CYP1A substrates and other substances sub-
ject to genetic variability.
Table 1. Ethnic variation of the cytochrome P450 CYP 2D6 [14].
Ethnicity PM U-RM
Caucasian 6-10% 1-10%
Asian 0-2% 1%
African 5% 5-29%
Middle Eastern 1-2% 21%
Amerindian 2.2-2.4% 0%
McGraw and Waller 2012 (and others)
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